Skip to search formSkip to main contentSkip to account menu

AC220

Known as: AC-220, AC010220 
National Institutes of Health

Related topics

Related topics

1 relation
Quizartinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.
7021 Background: Advanced age and FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) in acute myeloid leukemia… 
Review
2012
Review
2012
Molecular targeted therapy in acute myeloid leukemia
The treatment of acute myeloid leukemia has not changed significantly over the last 40 years. Recent progress in understanding… 
2012
2012
A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study
Background AC220 is a novel class III receptor tyrosine kinase (RTK) inhibitor that is potent and highly selective for mutant and… 
2011
2011
Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants
Abstract 930 Background: Activating mutations in FLT3 are detected in approximately 30 percent of adult acute myeloid leukemia… 
Highly Cited
2009
Highly Cited
2009
AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.
Abstract 636 Activating mutations in the FLT3 RTK are present in ∼30% of AML patients (pts), who have a significantly worse… 
Review
2009
Review
2009
FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status.
Abstract 1026 Poster Board I-48 Background: FLT3 mutations (ITD or D835 point mutation) are frequently observed in patients… 
2009
2009
AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenografts.
Abstract 2052 Poster Board II-29 AC220, a potent and selective FLT3 inhibitor, has a sub-nanomolar anti-proliferative EC 50… 
2008
2008
Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor
Activating mutations in the receptor tyrosine kinase FLT3 are present in approximately 30% of patients (pts) with acute myeloid… 
2008
2008
Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3
Several different FLT3 inhibitors have now been tested as monotherapy for AML patients and have met with only limited success. To… 
2007
2007
Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.
Introduction: Activating mutations in FLT3 are present in a significant fraction of acute myeloid leukemia (AML) cases. Patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)